Tag: NIH license
Vaxxas to develop first room-temperature stable RSV vaccine with NIH license
Vaxxas, a clinical-stage biotechnology company known for its innovative high-density microarray patch (HD-MAP) vaccination platform, has secured a worldwide license from the United States National Institutes of Health (NIH) for a next-generation vaccine antigen aimed at combating Respiratory Syncytial Virus (RSV).
Featured Article
Delivering growth: how invoice finance transformed a logistics business
For a smaller freight-forwarding company to compete with international behemoths, Global Trade Logistics founder Gary Coutsoudis knows he and his team must outperform.
